Nat Rev Cancer. 2009 Jun;9(6):415-28.

The biology of ovarian cancer: new opportunities for translation.

Source

Departments of Experimental Therapeutics and Systems Biology, University of Texas M. D. Anderson Cancer Center, 1515 Holcolmbe Boulevard, Houston, TX 77030, USA. rbast@mdanderson.org

Abstract

Over the past two decades, the 5-year survival for ovarian cancer patients has substantially improved owing to more effective surgery and treatment with empirically optimized combinations of cytotoxic drugs, but the overall cure rate remains approximately 30%. Many investigators think that further empirical trials using combinations of conventional agents are likely to produce only modest incremental improvements in outcome. Given the heterogeneity of this disease, increases in long-term survival might be achieved by translating recent insights at the molecular and cellular levels to personalize individual strategies for treatment and to optimize early detection.

PMID:: 19461667; [PubMed - indexed for MEDLINE]
PMCID: PMC2814299

Free PMC Article

Publication Types, MeSH Terms, Substances, Grant Support

Publication Types

MeSH Terms

Substances

Antineoplastic Agents

Grant Support

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Supplemental Content

Related citations

Review A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer. [Health Technol Assess. 2001]
Review A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
Clegg A, Scott DA, Sidhu M, Hewitson P, Waugh N. Health Technol Assess. 2001; 5(32):1-195.
Review Molecular targeted therapy in ovarian cancer: what is on the horizon? [Drugs. 2011]
Review Molecular targeted therapy in ovarian cancer: what is on the horizon?
Kalachand R, Hennessy BT, Markman M. Drugs. 2011 May 28; 71(8):947-67.
Review Relapsed ovarian cancer: challenges and management strategies for a chronic disease. [Oncologist. 2002]
Review Relapsed ovarian cancer: challenges and management strategies for a chronic disease.
Armstrong DK. Oncologist. 2002; 7 Suppl 5:20-8.
Review Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation. [Health Technol Assess. 2006]
Review Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
Main C, Bojke L, Griffin S, Norman G, Barbieri M, Mather L, Stark D, Palmer S, Riemsma R. Health Technol Assess. 2006 Mar; 10(9):1-132. iii-iv.
Review Investigational agents for epithelial ovarian cancer. [Expert Rev Anticancer Ther. 2005]
Review Investigational agents for epithelial ovarian cancer.
Muggia F, Kosloff R. Expert Rev Anticancer Ther. 2005 Oct; 5(5):855-68.

See reviews... See all...

Cited by 46 PubMed Central articles

An orthotopic model of platinum-sensitive high grade serous fallopian tube carcinoma. [Int J Clin Exp Pathol. 2012]
An orthotopic model of platinum-sensitive high grade serous fallopian tube carcinoma.
Khabele D, Fadare O, Liu AY, Wilson AJ, Wass E, Osteen K, Crispens MA. Int J Clin Exp Pathol. 2012; 5(1):37-45. Epub 2011 Jan 1.
Noninvasive Imaging Reveals Inhibition of Ovarian Cancer by Targeting CXCL12-CXCR4. [Neoplasia. 2011]
Noninvasive Imaging Reveals Inhibition of Ovarian Cancer by Targeting CXCL12-CXCR4.
Ray P, Lewin SA, Mihalko LA, Schmidt BT, Luker KE, Luker GD. Neoplasia. 2011 Dec; 13(12):1152-61.
An activating Pik3ca mutation coupled with Pten loss is sufficient to initiate ovarian tumorigenesis in mice. [J Clin Invest. 2012]
An activating Pik3ca mutation coupled with Pten loss is sufficient to initiate ovarian tumorigenesis in mice.
Kinross KM, Montgomery KG, Kleinschmidt M, Waring P, Ivetac I, Tikoo A, Saad M, Hare L, Roh V, Mantamadiotis T, et al. J Clin Invest. 2012 Feb 1; 122(2):553-7. Epub 2012 Jan 3.

See all...

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
References for this PMC Article
Citation referenced in PubMed article. Only valid for PubMed citations that are also in PMC.
Free in PMC
Free full text articles in PMC
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

The biology of ovarian cancer: new opportunities for translation.
The biology of ovarian cancer: new opportunities for translation.
Nat Rev Cancer. 2009 Jun ;9(6):415-28.

PubMed
Trends in treatment costs for localized prostate cancer: the healthy screenee ef...
Trends in treatment costs for localized prostate cancer: the healthy screenee effect.
Med Care. 2007 Feb ;45(2):154-9.

PubMed
Cost and quality: evidence from Ontario long term care hospitals.
Cost and quality: evidence from Ontario long term care hospitals.
Med Care. 2007 Oct ;45(10):981-8.

PubMed
Escherichia coli NsrR regulates a pathway for the oxidation of 3-nitrotyramine t...
Escherichia coli NsrR regulates a pathway for the oxidation of 3-nitrotyramine to 4-hydroxy-3-nitrophenylacetate.
J Bacteriol. 2008 Sep ;190(18):6170-7. Epub 2008 Jul 25 .

PubMed
Opiate abuse, innate immunity, and bacterial infectious diseases.
Opiate abuse, innate immunity, and bacterial infectious diseases.
Arch Immunol Ther Exp (Warsz). 2008 Sep-Oct ;56(5):299-309.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Display Settings:

Send to: